期刊文献+

循环肿瘤细胞与转移性前列腺癌患者预后关系的Meta分析 被引量:7

Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer:A Metaanalysis
下载PDF
导出
摘要 目的 通过Meta分析系统评价循环肿瘤细胞(circulating tumor cells, CTCs)与转移性前列腺癌患者的预后关系。方法 检索PubMed、EMbase、Cochrane图书馆、中国期刊全文数据库(CNKI)及中国生物医学文献数据库(CBM)等,收集患者血液中CTCs数量与前列腺癌Gleason评分0~10级的前列腺癌患者预后相关的研究。以总生存期(OS)为观察终点,采用Review Manager 5.3进行Meta分析。结果 共有10篇英文文献纳入Meta分析,结果显示CTCs阳性组较CTCs阴性组在总生存期(OS)上预后差(HR=2.47, 95%CI: 2.02~3.02, P〈0.00001),根据检测时间与检测方法进行亚组分析,CTCs阳性组比CTCs阴性组患者预后差。同时分析结果还提示CTCs阳性与前列腺癌Gleason评分呈正相关(OR=2.23, 95%CI: 1.41~3.53,P〈0.04)。与前列腺癌特异性抗原(PSA)水平、是否有骨外多发转移均无相关性。结论 外周血CTCs阳性是转移性前列腺癌患者预后的风险因素,且与检测时间、检查方法无关。 Objective To systematically review the prognostic value of circulating tumor cells(CTCs) for metastatic prostate cancer patients by Meta-analysis. Methods We electronically searched PubMed, EMbase, Cochrane Library, CNKI and CBM for collecting the studies about the prognostic relevance of CTCs in the peripheral blood of Gleason score 0-10th metastatic prostate cancer patients. The observation endpoint was the overall survival(OS). Review Manager 5.3 was used for this analysis. Results A total of 10 studies involving 1 137 patients of metastatic prostate cancer were eligible for the final analyses. The results of Metaanalysis showed that the presence of CTCs was associated with OS(HR=2.47, 95%CI: 2.02-3.02, P〈0.00001). According to the subgroup analysis by the detection time and the detection method, CTCs positive group show the poor prognosis than CTCs negative group patients. CTCs positive group showed a significantly positive correlation with the Gleason score of prostate cancer (OR=2.23, 95%CI: 1.41-3.53, P〈0.04), rather than PSA or extra bone metastasis. Conclusion CTCs is an adverse prognostic factor for metastatic prostate cancer patients, which is not significantly influenced by the detection time and check method.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第9期783-788,共6页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金(81071751) 暨南大学医学科学研究与应用组团联合项目(88016013031)
关键词 循环肿瘤细胞 转移性前列腺癌 预后 META分析 Circulating tumor cells Metastatic prostate cancer Prognosis Meta-analysis
  • 相关文献

参考文献23

  • 1韩苏军,张思维,陈万青,李长岭.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334. 被引量:762
  • 2Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines onProstate Cancer. Part 1: Screening, Diagnosis, and Treatment ofClinically Localised Disease[J]. Eur Urol, 2011, 59(1): 61-7.
  • 3汤元佳,何卫阳,苟欣.循环肿瘤细胞在去势抵抗性前列腺癌中的应用进展[J].现代医药卫生,2015,31(15):2287-2289. 被引量:2
  • 4Ashwoah TR. A case of cancer in which cells similar to those inthe tumors were seen in the blood after death[J]. Aust Med J,18 69, 14: 146-9.
  • 5胡玉倩,谢圣高,郑义,宁勇.循环肿瘤细胞的富集与检测研究进展[J].肿瘤防治研究,2014,41(7):834-838. 被引量:6
  • 6Joosse SA, Pantel K. Biologic challenges in the detection ofcirculating tumor cells[J]. Cancer Res, 2013, 73(1): 8-11.
  • 7Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomised studies in metaanalyses[EB/OL]. [2013-11-26]. http://www.ohri.ca/programs/clinical epidemiology/oxford.asp.
  • 8Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell countsare prognostic of overall survival in SWOG S0421: a phase iii trialof docetaxel with or without atrasentan for metastatic castrationresistantprostate cancer[J]. J Clin Oncol, 2014, 32(11): 1136-42.
  • 9Thalgott M, Rack B, Eiber M, et al. Categorical versus continuouscirculating tumor cell enumeration as early surrogate markerfor therapy response and prognosis during docetaxel therapy inmetastatic prostate cancer patients[J]. BMC Cancer, 2015, 15: 458.
  • 10Olmos D, Arkenau HT, Ang JE, et al. Circulating tumourcell(CTC) counts as intermediate end points in castration-resistantprostate cancer(CRPC): a single-centre experience[J]. Ann Oncol,2009, 20(1): 27-33.

二级参考文献70

  • 1赫杰,赵平,陈万青.2011中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:2-5,26 -37,74 -75.
  • 2Segi M. Cancer mortality for selected sites in 24 countries(1950-57 ) [ M ]. Japan : Department of Public Health,Tohoku Univer-sity of Medicine, 1960.
  • 3FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burdenof cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010,127(12) : 2893 -2917.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin’2011,61(2) :69 -90.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J].CA Cancer J Clin,2012,62( 1) :10 - 29.
  • 6Hanahan D, Weinberg RA. Hallmarks of cancer : The next genera- tion[J]. Cell,2011,144(5) :646 -674.
  • 7Ashworth TR. A ease of cancer in which cells similar to those in the turnouts were seen in the blood after death[ J]. Aust Med J, 1869, 14(32) :146 - 149.
  • 8Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial -mesenehymal transition [ J]. Nat Rev Mol Cell Biol, 2014, 15 (3) :178 -196.
  • 9Balie M, Lin H, Williams A, et al. Progress in circulating tumor cell capture and analysis : Implications for cancer management [ J ]. Ex- pert Rev Mol Diagn ,2012,12 ( 3 ) :303 - 312.
  • 10Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare eireu- lating tumor cells in cancer patients by mieor- el'lip teehnolgy[J]. Nature, 2007,450 ( 7173 ) : 1235 - 1239.

共引文献768

同被引文献45

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部